MGRX

+ Watchlist + Portfolio

Mangoceuticals, Inc.

Regulated industry Consumer brandTags from an AI model reading the company description.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $0.48
52-Week Range: $0.16 – $2.75
Market Cap: $9.43M
P/E (TTM): —
EPS (TTM): -1.02
Dividend Yield: 0.00%

Advanced Metrics

Price/Book: 0.63
PEG Ratio: —
Return on Equity: -95.10%
Return on Assets: -46.97%
Gross Margin: 54.43%
Operating Margin: -1502.45%
Profit Margin: 0.00%
Current Ratio: 0.18
Debt/Equity: 0.02
Total Debt: $279.21K
Free Cash Flow: $1.27M
Revenue Growth: -59.10%
Earnings Growth: —
Enterprise Value: $9.48M

MGRX Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$8.94K	$731.49K	$615.87K	$456.02K
Cost of Revenue	$4.09K	$299.99K	$235.91K	$205.63K
Gross Profit	$4.85K	$431.50K	$379.96K	$250.39K
Selling, General & Admin	$2.00M	$8.55M	$7.90M	$16.72M
Operating Expenses	$2.00M	$9.65M	$9.07M	$19.41M
Operating Income	-$1.99M	-$9.22M	-$8.69M	-$19.15M
EBITDA	-$1.99M	-$9.13M	-$7.96M	-$18.82M
Pretax Income	-$2.00M	-$9.21M	-$8.71M	-$20.64M
Income Tax	$0.00	$0.00	$0.00	$0.00
Net Income	-$2.00M	-$9.21M	-$8.71M	-$20.64M
Diluted EPS	-1.96	-8.58	-4.80	-2.17
Diluted Shares	1.02M	1.07M	1.98M	10.07M

MGRX Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$682.86K	$739.01K	$58.65K	$1.49M
Receivables	—	—	$0.00	$20.06K
Inventory	$0.00	$18.50K	$0.00	—
Current Assets	$694.61K	$835.40K	$75.59K	$1.55M
Total Assets	$1.00M	$1.05M	$15.37M	$16.09M
Current Liabilities	$260.58K	$211.08K	$1.43M	$890.57K
Total Debt	$352.87K	$128.68K	$214.96K	$307.82K
Total Liabilities	$389.26K	$276.04K	$1.43M	$890.57K
Retained Earnings	-$2.02M	-$11.23M	-$20.00M	-$40.65M
Shareholders' Equity	$614.03K	$774.75K	$13.95M	$15.20M
Working Capital	$434.03K	$624.32K	-$1.35M	$656.87K
Net Debt	—	—	$91.35K	—

MGRX Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$1.35M	-$7.00M	-$4.86M	-$5.85M
Capital Expenditure	-$43.10K	-$3.52K	—	—
Free Cash Flow	-$1.39M	-$7.00M	-$4.86M	-$5.85M
Depreciation & Amortisation	$3.86K	$79.87K	$731.47K	$1.72M
Stock-Based Compensation	$234.09K	$624.46K	$248.68K	$1.17M
Investing Cash Flow	-$43.10K	-$3.52K	$65.00K	$0.00
Financing Cash Flow	$2.05M	$7.06M	$4.13M	$7.27M
Net Change in Cash	$660.31K	$56.15K	-$670.51K	$1.42M

MGRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Revenue	$109.31K	$168.11K	$84.25K	$94.36K	$67.86K	$68.76K
Cost of Revenue	$47.24K	$78.16K	$33.35K	$46.88K	$38.86K	$24.54K
Gross Profit	$62.06K	$89.95K	$50.90K	$47.48K	$29.00K	$44.22K
Selling, General & Admin	$3.22M	$5.25M	$7.56M	$412.33K	$3.14M	$1.08M
Operating Expenses	$4.64M	$5.36M	$7.59M	$1.54M	$3.16M	$1.08M
Operating Income	-$4.58M	-$5.27M	-$7.54M	-$1.49M	-$3.13M	-$1.03M
EBITDA	-$4.15M	-$4.56M	-$7.52M	-$2.30M	-$2.83M	-$738.21K
Pretax Income	-$4.84M	-$5.42M	-$7.62M	-$2.77M	-$3.40M	-$1.31M
Income Tax	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Net Income	-$4.84M	-$5.42M	-$7.62M	-$2.77M	-$3.40M	-$1.31M
Diluted EPS	-1.12	-0.57	-0.69	—	-0.22	-0.09
Diluted Shares	4.59M	9.98M	11.52M	—	16.48M	17.12M

MGRX Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Cash & Equivalents	$76.50K	$101.02K	$481.28K	$1.49M	$174.56K	$228.69K
Receivables	—	—	—	$20.06K	$20.06K	$0.00
Inventory	$0.00	—	—	—	—	—
Current Assets	$176.65K	$117.96K	$598.22K	$1.55M	$212.47K	$245.69K
Total Assets	$21.75M	$20.84M	$16.53M	$16.09M	$14.45M	$14.17M
Current Liabilities	$1.50M	$1.60M	$804.27K	$890.57K	$737.61K	$1.40M
Total Debt	$47.71K	$630.12K	$112.17K	$307.82K	$294.02K	$324.15K
Total Liabilities	$1.50M	$1.60M	$804.27K	$890.57K	$974.57K	$1.65M
Retained Earnings	-$25.94M	-$31.65M	-$37.88M	-$40.65M	-$44.05M	-$45.36M
Shareholders' Equity	$20.25M	$19.24M	$15.73M	$15.20M	$13.48M	$12.53M
Working Capital	-$1.33M	-$1.48M	-$206.05K	$656.87K	-$525.13K	-$1.15M
Net Debt	—	$498.98K	—	—	—	—

MGRX Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026	Q2 2026
Operating Cash Flow	-$2.27M	-$1.26M	-$1.24M	-$1.08M	-$1.31M	-$260.51K
Free Cash Flow	-$2.27M	-$1.26M	-$1.24M	-$1.08M	-$1.31M	-$260.51K
Depreciation & Amortisation	$414.99K	$836.23K	$24.83K	$448.15K	$291.59K	$294.83K
Stock-Based Compensation	$50.98K	$50.98K	$1.10M	-$33.47K	$1.09M	$12.42K
Investing Cash Flow	—	—	$0.00	$0.00	—	—
Financing Cash Flow	$2.29M	$1.28M	$1.62M	$2.08M	$0.00	$316.94K
Net Change in Cash	$10.22K	$24.34K	$380.31K	$1.01M	-$1.31M	$56.44K

Market Snapshot

About

Mangoceuticals is a telemedicine and wellness company focused on men's health products. The company offers online consultations and direct-to-consumer pharmaceutical and nutraceutical solutions targeting male vitality and performance.